Comment from Bower, Kaylin
AnonymousSupportIndividual
Summary: An individual commenter is urging the FDA to implement stricter transparency and conflict-of-interest requirements for advocacy organizations involved in drug development meetings. They argue that organizations with significant industry funding should be required to disclose those financial ties to ensure the public can distinguish between independent patient testimony and industry-sponsored advocacy.
This comment regards FDA docket FDA-2026-N-3947: "Impacts of Patient-Focused Drug Development Meetings; Established of a Public Docket; Request for Information and Comments": *This is Comment 2 of 2 regarding the EveryLife Foundation*
Accordingly, I urge the FDA to adopt substantially stronger transparency and conflict-of-interest safeguards for advocacy organizations participating in regulatory proceedings.
At minimum, the FDA should require:
-Prominent disclosure of all pharmaceutical and biotechnology funding sources above defined thresholds
-Disclosure of the percentage of organizational revenue derived from industry funding
-Disclosure of founder, board, executive, and advisory relationships with regulated industry
-Clear differentiation between independent patient testimony and submissions from heavily industry-funded organizations
The patient voice is critically important. However, organizations substantially financed by regulated industry should not be presented to the Agency or the public as independent patient advocates without full and prominent disclosure of those financial relationships.